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Abstract
Background: the  new  generation  nebuliser  PARI
eFlowﾮ rapid allows a highly efficient aerosol delivery
at reduced  inhalation time. However, lung function
data during long-term use of this device are not avail-
able until now.
Methods:  70 clinically stable adult cystic fibrosis pa-
tients  participated  in  this  observation  study.  Lung
function tests were performed prospectively 12 weeks
after and again 9 to 12 months after switching the in-
halation device from a conventional jet nebulizer to
the PARI eFlowﾮ rapid. Lung function data were col-
lected retrospectively from the visits 1 year as well as
12 weeks prior to the switch-over. Lung function data
for all time points were only available for 59 patients.
treatment time and patient’s satification were record-
ed for both conventional and new nebuliser in all 70
patients.
Results: After 1 year of inhalation with eFlowﾮ rapid,
the mean change in FEV1% was – 1.4% (n = 59 pa-
tients).  the  decrease  in  FEV1  was  smaller  than  the
change in FEV1 after 1 year of inhalation with the
conventional jet nebuliser (control period, -3.1%), al-
though this difference was not statistically significant.
the same effect was seen in MEF25[%] (-2.6% with
conventional  nebuliser  compared  to  –1.6%  after
eFlowﾮ  rapid).  concerning  the  FVc,  there  was  a
greater improvement after 1 year of inhalation with
the eFlowﾮ rapid than with the jet nebuliser (+ 2.9%
vs. +1.1%). For PEF%, there was an increase during
the  control  period,  whereas  after  inhalation  with
eFlowﾮ rapid there was a decrease (+1.1% vs. –2.9%).
All  changes  were  not  significantly  different.  the
eFlowﾮ rapid  reduced  total  daily  inhalation  time  by
two-thirds  (conventional  nebuliser:  31.1  min/day;
eFlowﾮ rapid: 10.2 min/day, n = 70 patients)
Conclusion: Inhalation with the new nebuliser eFlow
rapid does not alter FEV1, FVc or PEF significantly
after 1 year of inhalation. the treatment time could be
reduced significantly by the eFlowﾮ rapid.   
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IntRoductIon:
cystic fibrosis is a multiorgan disease in which respira-
tory failure accounts for nearly 85 % of the mortality.
Lung destruction is caused by obstruction of the air-
ways due to dehydrated, thickened mucus, by resultant
endobronchial infection, and an exaggerated inflamma-
tory response leading to development of bronchiecta-
sis and progressive obstructive pulmonary disease. Ag-
gressive  multimodal  management  of  the  cystic  lung
disease has resulted in great improvements in length
and quality of life [1].
the delivery of aerosolized medication by nebuliser
is an important part of pharmacotherapy for mainte-
nance of lung function in cystic fibrosis [2]. the use
of inhaled aerosols provides a selective treatment of
the lungs as high drug concentrations can be achieved
in the airways without major systemic adverse events.
currently,  the  most  common  nebulisers  are  com-
pressed  air  driven  jet  nebulisers,  e.g.  the  advanced
breath enhanced nebulisers PARI Lc Plus or PARI Lc
star. Recently, new technologies have emerged based
on a perforated vibrating membrane. the motion of
the membrane is created by an annular piezo-electric
element, thus extruding liquid via the laser drilled per-
forated membrane and dispersing it into fine regularly
sized  droplets.  the  new  electronic  nebuliser  Pari
eFlowﾮ rapid may represent a significant advance in
aerosol  delivery  to  the  lungs,  as  the  variation  of
droplet size is significantly lower ￡s with conventional
jet nebulisers. the respirable fractions are comparable
(71.3%  with  eFlow,  70.1%  with  Lc  Plus).  with  the
eFlowﾮ,  treatment  time  can  be  reduced  significantly
from 17.4 minutes to 6.0 minutes for tobramycin and
from 4.4 minutes to 1.6 minutes for salbutamol, al-
though in that study the inhaled volumes were not ex-
actly the same [3]. therefore less time burden might
improve treatment adherence. However, little is known
about the long-term effect of this new technology on
lung function in cF patients.
After the launch of the eFlowﾮ rapid in germany in
early 2005, most of our patients asked for a prescrip-
tion for the new inhalation device during their routine
visits. this study assessed long-term lung function over
12 months in those patients with cystic fibrosis whose
health insurance companies permitted the prescription
and therefore could use the eFlowﾮ rapid.
MAtERIALs And MEtHods
Patients:
this prospective observational study was conducted at
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4) Naehrig_Umbruchvorlage  14.02.11  14:25  Seite 63the  center  for  Adult  cystic  Fibrosis  Patients  at  the
Medizinische  Klinik-Innenstadt  of  the  university  of
Munich.  the  diagnosis  of  cystic  fibrosis  was  docu-
mented by two sweat tests and/or two identifiable mu-
tations  consistent  with  cF,  accompanied  by  one  or
more  clinical  features  consistent  with  cF.  Inclusion
criteria  were  for  all  subjects:  a)  permission  of  the
healthcare insurance company to buy the new nebulis-
er  after  patient’s  request  for  a  prescription  during  a
routine visit, b)written informed consent prior to the
performance of any study related procedures, c) age
18 years and older. 
After  the  launch  of  the  new  Pari  eFlow  rapidﾮ,
seventy adult cF patients of our center participated in
the investigation. they all were clinically stable in the
opinion of their physicians. clinically stable was de-
fined as no clinical relevant worsening in symptoms or
lung function during the 4 weeks prior to the recruit-
ment time. 
Study design:
the investigations were conducted in accordance to
the  criteria  of  the  Helsinki  declaration  and  to  the
standards of good Medical Practice
Outcome parameters:
Primary  and  secondary  outcome  measures  were  de-
fined  prospectively.  the  primary  outcome  was  lung
function data after 9-12 months use of the new nebu-
liser compared to lung function data obtained with the
use of conventional nebuliser, secondary outcome pa-
rameter  was  treatment  time,  and  satisfaction  with
aerosol therapy. 
Methods:
Lung function parameters were assessed prospectively
eight to twelve weeks after the beginning of regular
use of the new inhalation device Pari eFlow rapidﾮ
and again nine to twelve months later. Lung functions
tests were done during routine visits at our out-patient
clinic with a standard spirometer (Viasys MasterLab,
H￶chberg, germany). In order to have a control peri-
od, we assessed lung function data retrospectively for
the time points eight to twelve weeks as well as 9-12
months prior to the replacement of the conventional
device with the new PARI eFlowﾮ rapid.
Patients were asked to estimate their inhalation time
(except dry powder inhaler) before the switch to the
eFlowﾮ rapid and during use of the new device and to
report their satisfaction with the use of the nebuliser
on a scale of 0-10 (0 = not satisfied at all, 10 = very
satisfied)  concerning  duration  of  inhalation  time,
cleaning of the device, integration into daily physio-
therapy and tolerability of the device.
Statistical Analysis:
data are expressed as mean ﾱ sd except for the analy-
sis of treatment satisfaction (median, range). Paired t-
tests for continuous variables were two-sided. wilcox-
on-test with exact significance was used for comparison
of ordinal scaled data (treatment satisfaction). P values
that were less than 0.05 were considered to indicate sta-
tistical significance. statistical analyses were performed
with sPss software (sPss Inc., Illinois, usA).
REsuLts
Study population:
between March and June 2005 70 patients (36 females,
34  males,  aged  18-53  years,  mean  age  32  years)  re-
ceived the new inhalation device and were therefore
included in our study. 45 patients (65%) inhaled an an-
tipseudomonal  antibiotic,  either  tobramycin  (tobI,
300 mg tobramycin, 32 patients) or colistin (colistin
cF, 1 mega colistine, 13 patients ). Five patients in-
haled  other  tobramycin  solutions  (either  tobrasixﾮ,
160  mg  tobramycin  or  gernebcinﾮ,  80  mg  tobra  -
mycin). 46 patients used dornase alpha (Pulmozymeﾮ)
for mucolytic therapy, 33 of these patients had a com-
bination  therapy  with  either  tobramycin  or  colistin.
Additionally, each patient received daily saline inhala-
tion therapy, either with isotonic (0.9%) or hypertonic
(5.85%) solution.
As the retrospective lung function data were avail-
able in only 59 patients, the statistical analysis of all
lung function values does only include data of 59 pa-
tients. 
Lung function (Table 1 (n = 59))
while inhaling with the conventional jet nebulisers, the
mean FEV1 at the beginning of the year was 2.38 l
(range  0.72-6.19  l),  which  is  67.2%  (range  26.2-
136.4%) predicted. After 9-12 months inhalation with
the conventional nebuliser, FEV1 decreased by 3.1%
to 2.22 l (range 0.84-6.37 l); 64.1%, p = 0.88, not sig-
nificant). Eight to twelve weeks after changing to the
eFlowﾮ rapid,  FEV1  remained  stable  (2.23  l,  range
0.66-5.94l;  65.0%).  nine  to  twelve  months  after  the
switch-over  to  the  new  nebuliser,  FEV1  was  2.24  l
(range 0.71-5.97 l, 63.6%, p = 0.61, not significant).
concerning the FVc, the increase was greater after 1
year of inhalation with eFlowﾮ rapid than with the jet
nebuliser (+ 2.9% vs. +1.1%). there were no statisti-
cally  significant  differences  in  data  for  PEF  and
MEF25 (see table 1). concerning MEF25 as a para-
meter for small airway disease, during the one year pe-
riod of inhalation with the conventional nebuliser we
observed a decrease of 0.09 l/sec (-2.7%). MEF25 in-
creased  after  8-12  weeks  of  inhalation  with  eFlow
rapidﾮ by 0.11 l/sec (+ 6%) and then decreased again
by 0.13 l/sec (-6%) after 9-12 months of inhalation
with the new device. neither the changes after 1 year
of  inhalation  with  conventional  nebuliser  nor  the
changes  after  the  switch-over  to  eFlowﾮ rapid  were
statistically significant.
Mean total inhalation time (Table 2), n = 70: 
with  the  conventional  jet  nebulisers,  the  estimated
mean total inhalation time was 31.3 min/day. with the
PARI eFlowﾮ rapid, inhalation time was significantly
reduced by two-thirds to 10.2 min/d. the reduction in
inhalation time was similar for all inhaled medications.
Tolerability of  conventional and new device (Table 3):
All 70 patients completed the whole observation peri-
od. no patient had to be withdrawn because of severe
adverse events or intolerability of the device. In con-
trast, patients considered the eFlowﾮ rapid significant-
ly superior to the conventional jet nebuliser both in
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median score for the jet nebulisers were 9 points (2-
10) for tolerability and 3 points (1-10) for inhalation
time. For the eFlowﾮ rapid, after 8-12 weeks of usage
the scores were 10 (5-10) for tolerability and 10 (3-10)
for  inhalation  time,  respectively.  these  differences
were statistically significant. Regarding cleaning or in-
tegration into physiotherapy, there were no significant
differences between both types of inhalation device.
dIscussIon
the major results of this observational study of a co-
hort of 70 adult patients with cystic fibrosis indicate a)
that the use of the new nebuliser PARI eFlowﾮ rapid
preserved lung function in 59 patients, b) that the new
nebuliser was well tolerated in all 70 patients, and c)
that the use of this device reduced significantly the in-
halation time.
Pari eFlowﾮ rapid is a lightweight, portable electron-
ic aerosol platform that utilizes advanced technology
to ensure the efficiency of medication delivery within
reduced treatment times. In spite of the common ap-
plication of aerosolized medications in the therapy of
cystic fibrosis and the increasing demand for the next
generation nebuliser PARI eFlowﾮ rapid, there are no
prospective randomized comparisons of the two nebu-
liser devices. there is, however, rapidly growing evi-
dence that the new generation of nebulisers are as ef-
fective as the standard jet nebuliser[4].E .g., in a 7 week
cross-over study Militz et al. observed a better FEV1%
with an increased volume of sodium chloride inhala-
tion solution (14.8 ml vs. 5.8 ml) using PARI eFlowﾮ
rapid [5]. within the limits of an observational study,
we found no significant differences in mean FEV1 in
59 patients changing from conventional jet nebulisers
to PARI eFlowﾮ rapid. there seems to be a small ad-
vantage in favour of the eFlowﾮ rapid, as the loss in
FEV1% after 1 year of inhalation with a conventional
nebuliser was –3.1% compared to -1.4% after one year
of inhalation with the eFlow rapidﾮ, and the increase
in FVc was slightly higher after the inhalation with the
eFlowﾮ rapid, but again these differences were statisti-
cally not significant. Furthermore, several other factors
(e.g. number of exacerbations) which might have an
impact on FEV1% have not been considered. 
the comparability in terms of effect on lung func-
tion  is  consistent  with  the  in  vitro  comparability  of
aerosol delivery characteristics from inhaled medica-
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Table  1. Lung function data of the control period (jet nebuliser) and the study period
(eFlowﾮ rapid), n = 59; Values are median (range)
Control period Jet Nebuliser Mean difference P
T1 T2 (T1 – T2)
FEV1 [%] 67.2 64.1 -3.1%
(26.2-136.4) (27.6-130.1)
FVc [%] 88.3 89.4 + 1.1%
(43.2-145) (44.4-142.1)
PEF [%] 63.6 65.0 +1.4%
(18.6-109.7) (23.2-108.3)
MEF 25[%] 15.6 13.0 -2.6%
(0.0-101.3) (3.0-89.0)
Study period eFlowﾮ rapid Mean difference P
T3 T4 (T3 – T4)
FEV1 [%] 65.0 63.6 -1.4%
(24.0-131.0) (222.0-131.6)
FVc [%] 86.0 88.9 +2.9%
(42.9-151.4) (30.9-151.0)
PEF [ %] 62.4 59.5 -2.9%
(17.1-113.2) (13.9-122.2)
MEF25 [%] 16.0 14.4 -1.6%
(0.0-278) (2.8-78.2)
Table  2.  comparison of treatment times with the conven-
tional jet nebuliser and the PARI eFlowﾮ rapid; n = 70 pa-
tients.
nebulised medication Jet nebuliser eFlowﾮ rapid
total inhalation time (min/d) 31.3 (21.4) 10.2 (8.3)
tobramycin (300 mg/5 ml) 24.3 (11.9) 8.4 (4.8)
colistine (79 mg/3 ml) 18.8 (8.7) 6.4 (2.1)
dornase alpha (2.5 mg/2.5 ml) 15.3 (8.1) 5.4 (4.2)
All data were presented as mean (sd). P < 0.01 for each row
comparing jet nebuliser und eFlowﾮ rapid
Table 3. Median tolerabiliy, inhalation time, cleaning and in-
tegration into the conventional therapy comparing jet nebu-
liser and eFlowﾮ rapid; n = 70 patients
Jet nebuliser eFlowﾮﾮ rapid p
tolerability 9 (2-10) 10 (5-10) 0.021
Inhalation time 3 (1-10) 10 (3-10) < 0.01
cleaning 7 (1-10) 7 (1-10) 0.93
Integration 7 (1-10) 7 (1-10) 0.95
All data were presented as median (range). both treatment
devices were compared using the wilcoxon test with exact
probabilities.  
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PARI Lc PLus [6]. the delivered and respirable doses
of tobramycin were found to be comparable with both
nebulisers  in  a  prospective,  randomized  (cross-over
design)  bio-equivalence  study  [6].  In  another  study
scherer et al. [7] showed, that the eFlowﾮ rapid deliv-
ers dornase alfa more rapidly and efficiently that jet
nebulizers,  and  does  not  affect  the  physiochemical
properties  of  the  drug.  they  also  showed  that  the
droplet size distribution of the eFlowﾮ rapid is nar-
rower than the droplet distribution of jet nebulizers.
geidel et al. investigated patients with cystic fibrosis
and found no effect of body position (either vertical
or horizontal) on serum tobramycin concentration [8].
two  pharmacokinetic  studies  compared  serum  and
sputum  tobramycin  levels  after  inhalation  of  to-
bramycin solution for inhalation either with PARI Lc
Plus or PARI eFlowﾮ rapid for 15 days. In the first
study  by  tavakkol  et  al.  [4]  the  serum  tobramycin
Auc after 15 days of inhalation was comparable in
both  devices,  whereas  the  sputum  concentration  of
tobramycin  was  higher  in  the  PARI  eFlowﾮ group.
this might lead to an even improved therapeutic ratio.
Furthermore, they found a reduction in treatment time
which is comparable to our study (17.7 min with Lc
Plus, 7.3 min with eFlowﾮ rapid). In the second study
conducted in France [9] systemic tobramycin exposure
in serum with eFlowﾮ rapid was broadly similar to that
observed from Lc Plus, particularly at day 15 (steady
state). they observed higher tobramycin sputum con-
centrations, although in both groups sputum concen-
trations were highly variable. In this study inhalation
time was reduced by one half with eFlowﾮ rapid (7.4
ﾱ 1.7 min for 5 ml tobI) compared to the Pari Lc
Plus (17.6 ﾱ 4.0 min for 5 ml tobI).
In canada, a deposition study was done by coates
et  al.  comparing  two  different  formulations  of  to-
bramycin  in  children  [10].  they  demonstrated  an
equivalent  dose  delivery  when  applying  300  mg  to-
bramycin in 5 ml saline via PARI Lc Plus compared to
300 mg tobramycin in 3 ml saline via eFlowﾮ rapid. 
In all 70 patients of our study, satisfaction with the
use  of  one  inhalation  device  was  greater  with  the
eFlowﾮ rapid than with the PARI Lc plus. one out-
standing  feature  of  the  electronic  nebuliser  is  the
much shorter treatment time due to the high aerosol
output rate, another feature is the more quiet opera-
tion. similarly, in the study by Militz et al. (5) eFlowﾮ
rapid was rated significantly better than the conven-
tional  device  (using  german  school  marks).  In  a
French study adherence to eFlowﾮ was assessed using
the cFQ14 questionnaire in 17 patients. In 8 patients
adherence significantly increased while inhalation time
decreased. An increase in quality of life was also ob-
served (11) whether the increase in mobility due to
long battery life (for up to 8 inhalations) adds to im-
proved adherence remains to be studied.
concLusIon
the use of the new inhalation device eFlowﾮ rapid
over one year does not alter significantly FEV1 and
FVc compared to one year of inhalation with a con-
ventional nebuliser, although concerning the changes
in  FEV1  there  seems  to  be  a  small  favour  for  the
eFlowﾮ rapid.  treatment  time  was  significantly  less
than with conventional nebulisers, therefore our pa-
tients preferred the new device. 
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